- Home
- GLBE vs LEGN Comparison
GLBE vs LEGN Comparison
Compare GLBE & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GLBE | LEGN |
|---|---|---|
| Founded | 2013 | 2014 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.7B | 5.9B |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | GLBE | LEGN |
|---|---|---|
| Price | $36.05 | $23.57 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 13 | 13 |
| Target Price | $49.46 | ★ $69.33 |
| AVG Volume (30 Days) | 966.8K | ★ 2.1M |
| Earning Date | 02-18-2026 | 03-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.04 | N/A |
| Revenue | $888,450,000.00 | ★ $909,045,000.00 |
| Revenue This Year | $29.12 | $68.20 |
| Revenue Next Year | $24.08 | $47.77 |
| P/E Ratio | $962.48 | ★ N/A |
| Revenue Growth | 31.57 | ★ 74.75 |
| 52 Week Low | $26.64 | $20.21 |
| 52 Week High | $63.69 | $45.30 |
Technical Indicators
Market Signals| Indicator | GLBE | LEGN |
|---|---|---|
| Relative Strength Index (RSI) | 35.67 | 51.91 |
| Support Level | $40.20 | $20.21 |
| Resistance Level | $41.66 | $24.12 |
| Average True Range (ATR) | 1.53 | 1.18 |
| MACD | -0.41 | 0.36 |
| Stochastic Oscillator | 1.56 | 88.23 |
Price Performance
Historical ComparisonAbout GLBE Global-E Online Ltd.
Global E Online Ltd provides e-commerce solutions. The company offers a platform to enable and accelerate direct-to-consumer cross-border e-commerce. The platform was purpose-built for international shoppers to buy seamlessly online and for merchants to sell from and anywhere in the world. The company localizes the shopper experience to make international transactions as seamless as domestic ones. The platform increases the conversion of international traffic into sales by removing much of the complexity associated with international e-commerce. The company derives maximum revenue from the United States.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.